Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 20 April 2021.
Search results
5 results
-
-
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 20 April 2021.
-
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 28 April 2021.
-
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375) [ID2710]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 28 April 2021.
-
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 26 April 2021.